Ranexa FDA Approval History
FDA Approved: Yes (First approved January 27, 2006)
Brand name: Ranexa
Generic name: ranolazine
Dosage form: Extended-Release Tablets
Company: CV Therapeutics, Inc.
Treatment for: Angina
Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.
Development timeline for Ranexa
| Date | Article |
|---|---|
| Nov 6, 2008 | Approval FDA Approves Ranexa for First Line Anti Anginal Use |
| Dec 19, 2007 | Approval FDA Approves New Mechanism of Action Labeling for Ranexa |
| Aug 14, 2007 | Approval CV Therapeutics Launches 1000 mg Ranexa Tablet |
| Jan 27, 2006 | Approval Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina |
| Jul 27, 2005 | CV Therapeutics Submits Amendment to Ranexa (ranolazine) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
